| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/27/2013 | WO2013092345A1 An inhaler comprising a tiotropium-containing-composition |
| 06/27/2013 | WO2013092284A1 Dialysis precursor composition |
| 06/27/2013 | WO2013092283A1 Dialysis precursor composition |
| 06/27/2013 | WO2013092269A1 Pharmaceutical compositions comprising glitazones and nrf2 activators |
| 06/27/2013 | WO2013092237A1 An inhalable medicament comprising tiotropium |
| 06/27/2013 | WO2013091994A1 Use of at least one anteiso-(c8-c30)-carboxylic acid for humidity-resistant heat styling |
| 06/27/2013 | WO2013091924A1 Applications of an immune system-released activating agent (israa) |
| 06/27/2013 | WO2013091900A1 Pipecolate-diketoamides for treatment of psychiatric disorders |
| 06/27/2013 | WO2013091897A1 Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| 06/27/2013 | WO2013091773A1 Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| 06/27/2013 | WO2013091704A1 Pharmaceutical composition comprising fingolimod |
| 06/27/2013 | WO2013091696A1 Synthesis of intermediates for preparing anacetrapib and derivatives thereof |
| 06/27/2013 | WO2013091631A1 Method of releasing nicotine from chewing gum |
| 06/27/2013 | WO2013091595A1 Pharmaceutical formulation of prasugrel hydrobromide |
| 06/27/2013 | WO2013091574A1 Pharmaceutical composition comprising candesartan or ester thereof and chlortalidone, and use thereof |
| 06/27/2013 | WO2013091539A1 Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
| 06/27/2013 | WO2013091507A1 Heterocycle amido alkyloxy substituted quinazoline derivative and use thereof |
| 06/27/2013 | WO2013091502A1 Tri-heterocyclic derivatives, preparation process and uses thereof |
| 06/27/2013 | WO2013091334A1 Use of rapamycin in preparing drugs for treating schizophrenia |
| 06/27/2013 | WO2013091285A1 Urea compound, preparation method and use thereof |
| 06/27/2013 | WO2013091282A1 Cajanine structure analogous compound, preparation method and use |
| 06/27/2013 | WO2013091144A1 Propenoate derivatives of betulin |
| 06/27/2013 | WO2013091096A1 Condensed triclyclic compounds as inhibitors of hiv replication |
| 06/27/2013 | WO2013091089A1 Three-dimensional cavities of dendritic cell immunoreceptor (dcir), compounds binding thereto and therapeutic applications related to inhibition of human immunodeficiency virus type-1 (hiv-1) |
| 06/27/2013 | WO2013091082A1 Bis-(aryl/heteroaryl)-methylene compounds, pharmaceutical compositions containing same and their use for treating cancer |
| 06/27/2013 | WO2013091053A1 Polymer composition containing natural bioactive principles for use in pharmaceutical and cosmetic formulations |
| 06/27/2013 | WO2013091052A1 Molecular compound comprising an acridine molecule chemically linked to a carboxylic group, which can be used for the selective destruction of solid tumour cells |
| 06/27/2013 | WO2013091014A1 Antimicrobial agents |
| 06/27/2013 | WO2013091011A1 Heterocyclic urea compounds |
| 06/27/2013 | WO2013090991A1 Tgf-beta therapy |
| 06/27/2013 | WO2013090989A1 Method of treating inflammatory bowel disease |
| 06/27/2013 | WO2013090986A1 Treatment of seborrhoea |
| 06/27/2013 | WO2013066208A3 Pharmaceutical composition based on epigallocatechin gallate-containing nano-micelles and use thereof |
| 06/27/2013 | WO2013066134A3 Novel cinnamyl-rhodanine derivatives and pharmaceutical composition comprising same as active ingredients |
| 06/27/2013 | WO2013064919A9 Quinazoline derivatives with hsp90 inhibitory activity |
| 06/27/2013 | WO2013064703A9 Fkbp subtype-specific rapamycin analogue for use in treatment of diseases |
| 06/27/2013 | WO2013063462A3 Method of treating hcv infection with a small molecule chk2 inhibitor |
| 06/27/2013 | WO2013062442A3 Composition for the treatment of multiple sclerosis (variants) |
| 06/27/2013 | WO2013061328A8 Methods of treating cancer |
| 06/27/2013 | WO2013061205A3 (4 - phenylimidazol - 2 - yl) ethylamine derivatives usful as sodium channel modulators |
| 06/27/2013 | WO2013059837A3 Systems and methods for corneal cross-linking with pulsed light |
| 06/27/2013 | WO2013058774A8 Compositions comprising ascorbic acid and an imaging agent and related methods |
| 06/27/2013 | WO2013056108A3 Solid dispersions of a erb2 (her2) inhibitor |
| 06/27/2013 | WO2013055386A3 Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| 06/27/2013 | WO2013044028A3 Mycophenolic acid analogues as anti-tumor chemosensitizing agents |
| 06/27/2013 | WO2013043580A3 Modified creatine compounds |
| 06/27/2013 | WO2013041519A9 Ror gamma modulators |
| 06/27/2013 | WO2013038200A3 Neurodevelopmental disorders |
| 06/27/2013 | WO2013034979A3 Crystalline forms of cabazitaxel |
| 06/27/2013 | WO2013024474A8 Polymorphs of preladenant |
| 06/27/2013 | WO2012143796A3 Anti-inflammation compounds |
| 06/27/2013 | WO2012114204A3 Methods of treating mitochondrial dysfunction |
| 06/27/2013 | WO2012099942A3 Methods and compositions for treating metabolic syndrome |
| 06/27/2013 | WO2012080272A3 Leave-on non-solid skin conditioning compositions containing 12-hydroxystearic acid and ethoxylated hydrogenated castor oil |
| 06/27/2013 | WO2012065680A3 Dihydroxyfumaric acid derivatives, and use thereof for bleaching skin |
| 06/27/2013 | US20130165645 4-isopropyl-6-methoxyphenyl glucitol compound |
| 06/27/2013 | US20130165634 Expression and export of angiogenesis inhibitors as immunofusins |
| 06/27/2013 | US20130165529 Piceatannol-containing composition and method of producing piceatannol-containing composition |
| 06/27/2013 | US20130165527 Method for Administering an NMDA Receptor Antagonist to a Subject |
| 06/27/2013 | US20130165524 Trans-clomiphene for metabolic syndrome |
| 06/27/2013 | US20130165523 Compounds useful for treating and/or preventing disease-associated bone loss |
| 06/27/2013 | US20130165522 Gel formulations for the topical use of 1-amino-alkylcyclohexane derivatives |
| 06/27/2013 | US20130165521 Treatment of fungal infections |
| 06/27/2013 | US20130165519 Method of Bowel Cleansing |
| 06/27/2013 | US20130165518 Ibuprofen and narcotic analgesic compositions |
| 06/27/2013 | US20130165517 Composition and Method for Treating Neurological Disease |
| 06/27/2013 | US20130165516 Acetylcysteine Composition and Uses Thereof |
| 06/27/2013 | US20130165514 Orally administered composition and dietary composition having serum lipid improving effect |
| 06/27/2013 | US20130165513 Stable pharmaceutical composition and methods of using same |
| 06/27/2013 | US20130165511 Treatment for cocaine addiction |
| 06/27/2013 | US20130165510 Trypsin-like serine protease inhibitors, and their preparation and use |
| 06/27/2013 | US20130165508 Methods and formulations for treating ineffective or decreased esophagal motility |
| 06/27/2013 | US20130165505 1-phenylalkanecarboxylic acid derivatives for the treatment of cognitive impairment |
| 06/27/2013 | US20130165504 Methods of increasing the viability or longevity of an organ or organ explant |
| 06/27/2013 | US20130165502 Diagnostic, Prognostic and Therapeutic Uses of miRs in Adaptive Pathways and Disease Pathways |
| 06/27/2013 | US20130165500 RNA Interference Mediated Inhibition of Prolyl Hydroxylase Domain 2 (PHD2) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 06/27/2013 | US20130165499 Methods And Compositions For Prevention Or Treatment Of RSV Infection |
| 06/27/2013 | US20130165497 Monitoring of immune system using peripheral blood micro-rna expression profile analysis and uses thereof |
| 06/27/2013 | US20130165495 Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors |
| 06/27/2013 | US20130165494 1,5-Diaryl-2-alkylpyrrole-3-Substituted Nitro Esters, Selective COX-2 Inhibitors and Nitric Oxide Donors |
| 06/27/2013 | US20130165489 Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| 06/27/2013 | US20130165488 Novel Thromboxane A2 (TP) Receptor Antagonists |
| 06/27/2013 | US20130165484 Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients |
| 06/27/2013 | US20130165483 Heteroaryls and uses thereof |
| 06/27/2013 | US20130165481 Small-volume oral transmucosal dosage forms |
| 06/27/2013 | US20130165480 Stabilized and Preserved Ketotifen Ophthalmic Compositions |
| 06/27/2013 | US20130165478 Pyrazolopyridinone derivatives as lpa receptor antagonists |
| 06/27/2013 | US20130165474 Compounds that inhibit tau phosphorylation |
| 06/27/2013 | US20130165473 Azaquinolinone Derivatives and Uses Thereof |
| 06/27/2013 | US20130165472 Heteroaryls and uses thereof |
| 06/27/2013 | US20130165470 Methods for Detecting and Treating Rhinovirus Infection |
| 06/27/2013 | US20130165469 Novel neuromodulatory compounds |
| 06/27/2013 | US20130165468 Topical peripheral neuro-affective (tpna) therapy |
| 06/27/2013 | US20130165466 Polymer conjugates of opioid antagonists |
| 06/27/2013 | US20130165464 Heteroaryls and uses thereof |
| 06/27/2013 | US20130165463 Inhibition of focal adhesion kinase for control of scar tissue formation |
| 06/27/2013 | US20130165461 Methods of treating heart failure |
| 06/27/2013 | US20130165459 Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| 06/27/2013 | US20130165458 Quinazoline compounds as kinase inhibitors |
| 06/27/2013 | US20130165457 Inhibitors of e1 activating enzymes |